Search Result

Results for "

JAK-IN-3

" in MedChemExpress (MCE) Product Catalog:

By Targets:	JAK (25) Akt (3) Apoptosis (19) Aurora Kinase (3) Autophagy (8) Bacterial (1) Bcl-2 Family (1) Bcr-Abl (3) c-Myc (1) Deubiquitinase (1) Dopamine Receptor (1) EGFR (4) Endogenous Metabolite (2) Ferroptosis (2) FLT3 (3) Fungal (1) Glucocorticoid Receptor (1) Influenza Virus (1) Interleukin Related (2) Isotope-Labeled Compounds (4) Oxidative Phosphorylation (1) PI3K (1) PROTACs (1) Reference Standards (3) RET (1) STAT (12) TGF-β Receptor (1)
By Research Areas:	Cancer (30) Cardiovascular Disease (2) Infection (1) Inflammation/Immunology (18)

By Targets:

JAK (25)

Akt (3)

Apoptosis (19)

Aurora Kinase (3)

Autophagy (8)

Bacterial (1)

Bcl-2 Family (1)

Bcr-Abl (3)

c-Myc (1)

Deubiquitinase (1)

Dopamine Receptor (1)

EGFR (4)

Endogenous Metabolite (2)

Ferroptosis (2)

FLT3 (3)

Fungal (1)

Glucocorticoid Receptor (1)

Influenza Virus (1)

Interleukin Related (2)

Isotope-Labeled Compounds (4)

Oxidative Phosphorylation (1)

PI3K (1)

PROTACs (1)

Reference Standards (3)

RET (1)

STAT (12)

TGF-β Receptor (1)

By Research Areas:

Cancer (30)

Cardiovascular Disease (2)

Infection (1)

Inflammation/Immunology (18)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: JAK Dan family AIM2 NEKs CD44

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-111750

*JAK-IN-3*	JAK	Inflammation/Immunology
JAK-IN-3 (compound 22) is a potent JAK inhibitor, with IC₅₀ values of 3 nM, 5 nM, 34 nM and 70 nM for JAK3, JAK1, TYK2 and JAK2, respectively .

HY-N1447

Ganoderic acid A 5+ Cited Publications	Apoptosis Autophagy Endogenous Metabolite	Cancer
Ganoderic acid A can inhibit of the *JAK-STAT3* signaling pathway, also inhibit proliferation, viability, ROS.

HY-40354

Tofacitinib 80+ Cited Publications TasocitINib; CP-690550	JAK Apoptosis	Inflammation/Immunology Cancer
Tofacitinib is an orally available *JAK3/2/1* inhibitor with IC₅₀s of 1, 20, and 112 nM, respectively.

HY-12000

AG490 Maximum Cited Publications 153 Publications Verification TyrphostIN AG490; TyrphostIN B42	EGFR STAT JAK Autophagy	Cancer
AG490 (Tyrphostin AG490) is a tyrosine kinase inhibitor that inhibits EGFR, *Stat-3* and *JAK2/3*.

HY-156621

Lepzacitinib	JAK	Inflammation/Immunology
Lepzacitinib is a Janus kinase inhibitor targeting to JAK 1/3. Lepzacitinib exhibits anti-inflammatory effect and inhibits atopic dermatitis and other skin diseases .

HY-11067

WHI-P97 2 Publications Verification	JAK	Inflammation/Immunology
WHI-P97 is a potent and selective *JAK-3* inhibitor. WHI-P97 is effective in preventing the development allergic asthma in vivo .

HY-151285

JAK-2/3-IN-3	Apoptosis JAK	Inflammation/Immunology Cancer
JAK-2-/3-IN-3 (compound ST4j) is a potent *JAK2/3* inhibitor with IC₅₀s of 13.00 and 14.86 nM for JAK2 and *JAK3, respectively. JAK-2-/3-IN-3 inhibits autophosphorylation of JAK2* and induces apoptosis in a dose- and time-dependent manner. JAK-2-/3-IN-3 can be used in studies of lymph derived diseases and leukemia .

HY-10652

JAK-2/3-IN-1	JAK	Inflammation/Immunology Cancer
JAK-2/3-IN-1 is a potent JAK-2 and *JAK-3* inhibitor extracted from patent US8163732B2, compound 46, has K_is of <250 nM for both isoforms .

HY-N12473

25-Deacetylcucurbitacin A	JAK	Inflammation/Immunology
25-Deacetylcucurbitacin A is a Cucurbitane-Type triterpenoid and has the potential to be an anti-cancer agent and JAK/STAT3 signaling pathway inhibitor .

HY-151256

JAK-2/3-IN-2	JAK	Cancer
JAK-2/3-IN-2 (Compound 3h) is a JAK2 and *JAK3* inhibitor with IC₅₀s of 23.85 nM and 18.9 nM, respectively .

HY-40354A

Tofacitinib citrate 80+ Cited Publications TasocitINib citrate; CP-690550 citrate	JAK Apoptosis Bacterial Fungal Influenza Virus	Infection Inflammation/Immunology Cancer
Tofacitinib citrate is an orally available *JAK3/2/1* inhibitor with IC₅₀s of 1, 20, and 112 nM, respectively. Tofacitinib citrate has antibacterial, antifungal and antiviral activities.

HY-N1447R

Ganoderic acid A (Standard)	Reference Standards Apoptosis Autophagy Endogenous Metabolite	Cancer
Ganoderic acid A (Standard) is the analytical standard of Ganoderic acid A. This product is intended for research and analytical applications. Ganoderic acid A can inhibit of the JAK-STAT3 signaling pathway, also inhibit proliferation, viability, ROS.

HY-40354S

Tofacitinib-13C3 TasocitINib-¹³C₃; CP-690550-¹³C₃	JAK Apoptosis	Inflammation/Immunology Cancer
Tofacitinib- ¹³C₃ is the ¹³C-labeled Tofacitinib. Tofacitinib is an orally available JAK3/2/1 inhibitor with IC50s of 1, 20, and 112 nM, respectively.

HY-40354S3

Tofacitinib-13C TasocitINib-¹³C; CP-690550-¹³C	Isotope-Labeled Compounds	Inflammation/Immunology Cancer
Tofacitinib- ¹³C (Tasocitinib- ¹³C) is ¹³C labeled Tofacitinib. Tofacitinib is an orally available *JAK3/2/1* inhibitor with IC₅₀s of 1, 20, and 112 nM, respectively.

HY-40354R

Tofacitinib (Standard) TasocitINib (Standard); CP-690550 (Standard)	Reference Standards JAK Apoptosis	Inflammation/Immunology Cancer
Tofacitinib (Standard) is the analytical standard of Tofacitinib. This product is intended for research and analytical applications. Tofacitinib is an orally available *JAK3/2/1* inhibitor with IC₅₀s of 1, 20, and 112 nM, respectively.

HY-40354S5

Tofacitinib-d3 TasocitINib-d₃; CP-690550-d₃	Isotope-Labeled Compounds	Inflammation/Immunology Cancer
Tofacitinib-d₃ (Tasocitinib-d₃) is deuterium labeled Tofacitinib. Tofacitinib is an orally available *JAK3/2/1* inhibitor with IC₅₀s of 1, 20, and 112 nM, respectively.

HY-103438A

BIBU1361 dihydrochloride	Apoptosis Autophagy Akt	Cancer
BIBU1361 dihydrochloride induces apoptosis and inhibits autophagy. BIBU1361 inhibits pro-survival pathways Akt/mTOR and *gp130/JAK/STAT3, and decreased levels of pro-inflammatory cytokine IL-6* .

HY-103438

BIBU1361	Apoptosis Akt Autophagy	Cancer
BIBU1361 induces apoptosis and inhibits autophagy. BIBU1361 inhibits pro-survival pathways Akt/mTOR and *gp130/JAK/STAT3, and decreased levels of pro-inflammatory cytokine IL-6* .

HY-40354S2

Tofacitinib-13C,d3 TasocitINib-¹³C,d₃; CP-690550-¹³C,d₃	Isotope-Labeled Compounds	Inflammation/Immunology Cancer
Tofacitinib- ¹³C,d₃ (Tasocitinib- ¹³C,d₃) is ¹³C labeled Tofacitinib. Tofacitinib is an orally available *JAK3/2/1* inhibitor with IC₅₀s of 1, 20, and 112 nM, respectively.

HY-E70789

BCR-RET Recombinant Human Active Protein Kinase	RET	Others
BCR-RET Recombinant Human Active Protein Kinase is a BCR-RET fusion protein in hematopoietic malignancies. BCR-RET overactivates the Ras-ERK pathway, in addition to JAK/STAT3 and PI3K/AKT pathways .

HY-40354S1

Tofacitinib-13C3,15N TasocitINib-¹³C₃,¹⁵N; CP-690550-¹³C₃,¹⁵N	Isotope-Labeled Compounds JAK Apoptosis	Inflammation/Immunology Cancer
Tofacitinib- ¹³C₃, ¹⁵N (Tasocitinib- ¹³C₃, ¹⁵N) is ¹³C and ¹⁵N labeled Tofacitinib. Tofacitinib is an orally available *JAK3/2/1* inhibitor with IC₅₀s of 1, 20, and 112 nM, respectively.

HY-107459

(E/Z)-AG490 (E/Z)-TyrphostIN AG490; (E/Z)-TyrphostIN B42	EGFR STAT JAK	Cancer
(E/Z)-AG490 ((E/Z)-Tyrphostin AG490) is a racemic compound of (E)-AG490 and (Z)-AG490 isomers. (E)-AG490 (HY-12000) is a tyrosine kinase inhibitor that inhibits EGFR, *Stat-3* and *JAK2/3*.

HY-50514

AT9283 5+ Cited Publications	JAK Aurora Kinase Bcr-Abl FLT3 Apoptosis Autophagy	Cancer
AT9283 is a multi-targeted kinase inhibitor with potent activity against Aurora A/B, *JAK2/3, Abl (T315I)* and *Flt3* (IC₅₀s ranging from 1 to 30 nM). AT9283 inhibits growth and survival of multiple solid tumors in vitro and in vivo .

HY-10058

AT9283 lactic acid	JAK Aurora Kinase Bcr-Abl FLT3 Apoptosis Autophagy	Cancer
AT9283 lactic acid is a multi-targeted kinase inhibitor with potent activity against Aurora A/B, *JAK2/3, Abl (T315I)* and *Flt3* (IC₅₀s ranging from 1 to 30 nM). AT9283 lactic acid inhibits growth and survival of multiple solid tumors in vitro and in vivo .

HY-N2409

Delphinidin chloride 1 Publications Verification	Apoptosis EGFR JAK STAT	Cardiovascular Disease Cancer
Delphinidin chloride is an anthocyanin isolated from berries and red wine. Delphinidin chloride exhibits endothelium-dependent vasodilation and anticancer activity. Delphinidin chloride also modulates *JAK/STAT3* and MAPK signaling, thereby inducing apoptosis in HCT116 cells. Delphinidin chloride is also a potent inhibitor of EGFR (IC₅₀: 1.3 μM), shutting down downstream signaling cascades ^[3] .

HY-107595

SD-1008 1 Publications Verification	JAK STAT Apoptosis	Cancer
SD-1008 is a potent JAK inhibitor. SD-1008 inhibits tyrosyl phosphorylation of STAT3, JAK2 and Src. SD-1008 also reduces STAT3-dependent luciferase activity. SD-1008 enhances apoptosis induced by Paclitaxel in ovarian cancer cells via directly blocking the JAK-STAT3 signaling pathway .

HY-50514R

AT9283 (Standard)	JAK Aurora Kinase Bcr-Abl FLT3 Apoptosis Autophagy	Cancer
AT9283 (Standard) is the analytical standard of AT9283. This product is intended for research and analytical applications. AT9283 is a multi-targeted kinase inhibitor with potent activity against Aurora A/B, JAK2/3, Abl (T315I) and Flt3 (IC50s ranging from 1 to 30 nM). AT9283 inhibits growth and survival of multiple solid tumors in vitro and in vivo .

HY-150538

STAT3-IN-12 1 Publications Verification	STAT Apoptosis	Cancer
STAT3-IN-12 is a potent *STAT3* signal inhibitor that can inhibit IL-6 induced JAK/STAT3 signalling pathway activation. STAT3-IN-12 inhibits cancer cell growth, migration, and induce cell apoptosis as well as cycle arrest. STAT3-IN-12 can be used in cancer-related research, such as hepatocellular carcinoma (HCC) and oesophageal carcinoma .

HY-153190A

W1131 TFA	Ferroptosis STAT	Cancer
W1131 TFA is a potent STAT3 inhibitor that induces ferroptosis. W1131 inhibits cancer progression in subcutaneous xenograft, organoid, and PDX models of gastric cancer. W1131 effectively alleviates cancer cell chemoresistance to 5-FU (HY-90006). W1131 regulates the cell cycle, DNA damage response, and oxidative phosphorylation, including the IL6-JAK-STAT3 pathway and the ferroptosis pathway .

HY-N2409R

Delphinidin chloride (Standard)	Apoptosis EGFR JAK STAT Reference Standards	Cardiovascular Disease Cancer
Delphinidin (chloride) (Standard) is the analytical standard of Delphinidin (chloride). This product is intended for research and analytical applications. Delphinidin chloride is an anthocyanin isolated from berries and red wine. Delphinidin chloride exhibits endothelium-dependent vasodilation and anticancer activity. Delphinidin chloride also modulates JAK/STAT3 and MAPK signaling, thereby inducing apoptosis in HCT116 cells. Delphinidin chloride is also a potent inhibitor of EGFR (IC50: 1.3 μM), shutting down downstream signaling cascades ^[3] .

HY-153190

W1131	Oxidative Phosphorylation STAT Ferroptosis	Cancer
W1131 is a potent *STAT3* inhibitor, triggering ferroptosis. W1131 suppresses cancer progression in gastric cancer cell subcutaneous xenograft model, organoids model, and PDX model. W1131 effectively alleviates chemical resistance of cancer cells to 5-FU (HY-90006). W1131 regulates cell cycle, DNA damage response, and oxidative phosphorylation, including *IL6-JAK-STAT3* pathway and ferroptosis pathway .

HY-175771

STAT3-IN-46	STAT c-Myc Bcl-2 Family Interleukin Related JAK	Cancer
STAT3-IN-46 is a selective and orally active inhibitor of signal transducer and activator of transcription 3 (STAT3) (K_D = 323.3 nM). STAT3-IN-46 directly binds to the SH2 domain of the STAT3 and inhibits IL-6/JAK/STAT3 signaling pathway (IC₅₀ = 0.87 μM) and downregulates c-Myc and Bcl-2 levels. STAT3-IN-46 can be used for the research of cancer, such as triple-negative breast cancer .

HY-176876

Glucocorticoid receptor/IL-6-IN-1	Glucocorticoid Receptor Interleukin Related JAK STAT	Inflammation/Immunology
Glucocorticoid receptor/IL-6-IN-1 (Compound 35) is a selective dual inhibitor targeting the glucocorticoid receptor (GR) and IL-6 signaling pathway (IC₅₀ values of 120 nM and 59 nM, respectively). Glucocorticoid receptor/IL-6-IN-1 inhibits IL-6-induced JAK/STAT3 phosphorylation, blocking inflammatory cytokine transcription. Glucocorticoid receptor/IL-6-IN-1 is promising for research of inflammatory diseases like rheumatoid arthritis and asthma .

HY-120920

UNC9995	Dopamine Receptor	Inflammation/Immunology
UNC9995 is a β-arrestin2-biased agonist of dopamine receptor Drd2. UNC9995 inhibits NLRP3 inflammasome activation by enhancing *β-arrestin2-NLRP3* interaction, thus prevents neuronal degeneration. Futhermore, UNC9995 activates the Drd2/β-arrestin2 signaling to prevent inflammation-related genes transcription-induced by *JAK/STAT3*. UNC9995 improves depressive behavior in mouse model, and improves astrocytes dysfunctions .

HY-145696

SJ10542	PROTACs JAK	Inflammation/Immunology Cancer
SJ10542 is a potent and selective JAK2/3 PROTAC degrader. In PDX cells lSJBALL020589, SJ10542 has DC₅₀ values of 14 and 11 nM for JAK2 and *JAK3*, respectively. SJ10542 exhibits antitumor activity and can be used for the research of hematological malignancies and autoimmune diseases . (Pink: Target protein ligand (HY-47073); Black: Linker (HY-W251248); Blue: E3 ligase ligand (HY-W890189); E3 ligase ligand+Linker (HY-176425))

HY-178500

WCY-8-67	Deubiquitinase Apoptosis STAT JAK Akt PI3K	Cancer
WCY-8-67 is an orally active and selective USP5 inhibitor, with an IC₅₀ value of 1.33 μM. WCY-8-67 induces apoptosis and suppresses *JAK/STAT3* and *PI3K/AKT* signaling pathways in vitro. WCY-8-67 inhibits proliferation of AE-positive AML cells, induces G1 phase arrest and differentiation of AML cells. WCY-8-67 demonstrates potent anti-leukemic efficacy in mice. WCY-8-67 can be used for the study of acute myeloid leukemia .

HY-N7694

Isotoosendanin 1 Publications Verification	TGF-β Receptor JAK STAT Apoptosis	Inflammation/Immunology Cancer
Isotoosendanin is an orally active TGFβR1 inhibitor and abrogating its kinase activity (IC₅₀ = 6732 nM). Isotoosendanin inhibits the *JAK/STAT3* signaling pathway by directly targeting SHP-2, enhancing its stability, and reducing its ubiquitination. Isotoosendanin inhibits TGF-β-induced reduces the migration, invasion, and metastasis in triple-negative breast cancer (TNBC) cells. Isotoosendanin exhibits anti-tumor efficacy in TNBC xenograft models and A549 xenograft tumors. Isotoosendanin exhibits significant anti-inflammatory effects in acetic acid-induced vascular permeability and λ-carrageenan-induced hind paw edema tests. Isotoosendanin can be used for the study of non-small cell lung cancer (NSCLC), TNBC and inflammation ^[3].

Cat. No.	Product Name	Category	Target	Chemical Structure